FIELD: medicine; allergology and dermatology.
SUBSTANCE: method of treatment of moderate or severe atopic dermatitis (AD) in a patient aged ≥12 and <18 years is proposed. An IL-4R inhibitor is administered to a patient weighing <60 kg, which is an antibody or antigen-binding fragment characterized by amino acid sequences of complementarity-determining regions (CDRs) with SEQ ID NO: 3–8 at 200 mg every two weeks (Q2W) with or without a loading dose of 400 mg. For a patient weighing ≥60 kg, the said IL-4R inhibitor is administered at 300 mg every two weeks (Q2W) with or without a loading dose of 600 mg.
EFFECT: invention provides an effective treatment of moderate or severe AD through these modes of administration.
26 cl, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR INCREASING VACCINE EFFICIENCY BY INJECTING IL-4R ANTAGONIST | 2017 |
|
RU2753869C2 |
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | 2017 |
|
RU2759630C2 |
| METHODS FOR TREATMENT OF ACTIVE EOSINOPHILIC ESOPHAGITIS | 2018 |
|
RU2776651C2 |
| TREATMENT OF IgE-MEDIATED ALLERGIC DISEASES | 2018 |
|
RU2800765C2 |
| METHODS OF TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2734490C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST | 2018 |
|
RU2793745C2 |
| ANTIBODIES TO B7-H1 AND CTLA-4 FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | 2015 |
|
RU2806210C2 |
| ANTIBODIES TO CD40 FOR USE IN THE TREATMENT OF SJOGREN'S SYNDROME | 2018 |
|
RU2790558C2 |
